By Nana O 
Immune therapy has fundamentally reshaped the landscape of cancer treatment, offering new hope for patients battling a wide array of malignancies. However, a persistent challenge remains: many tumors possess an uncanny ability to elude the immune system’s detection. This evasion is often attributed to the tumors’ striking resemblance to healthy tissues, making it difficult for the body’s natural defenses, or even engineered immunotherapies, to distinguish friend from foe. This sophisticated camouflage has historically limited the efficacy of treatments for some of the most aggressive and intractable cancers.
Now, a groundbreaking study conducted by researchers at the University of California, San Francisco (UCSF) has illuminated a critical vulnerability in this defense mechanism. Their work reveals that certain aggressive cancers, including deadly brain tumors like glioma, produce distinct, aberrant proteins—termed neoantigens—that are demonstrably different from those found in healthy cells. These newly identified cancer-specific proteins hold immense potential to accelerate the development of more potent and targeted immunotherapies, capable of recognizing and eradicating even the most resilient tumors.
The findings, supported by substantial grants from the National Institutes of Health (NIH), were published on February 19th in the prestigious scientific journal Nature. This discovery marks a significant leap forward in our understanding of tumor biology and opens a promising new avenue for therapeutic intervention.
The Genesis of Cancer-Specific Antigens: Errors in RNA Splicing
The research team’s pivotal insight lies in the mechanism behind the creation of these unique cancer antigens: errors in RNA splicing. RNA splicing is a fundamental cellular process that acts as a molecular editor, dictating how messenger RNA (mRNA) molecules—the blueprints for protein synthesis—are assembled from various segments. In healthy cells, this process is meticulously controlled, ensuring the production of functional proteins. However, the UCSF study has demonstrated that in a range of cancers, including those affecting the brain, prostate, liver, and colon, this splicing machinery malfunctions.
These splicing errors lead to the creation of novel mRNA sequences that are never found in normal tissues. The researchers discovered that in these cancerous cells, bits of RNA are erroneously stitched together, forming hybrid or truncated transcripts. These aberrant transcripts then serve as templates for the production of entirely new proteins, or altered versions of existing ones, that are unique to the tumor.
Crucially, some of these newly synthesized proteins, when expressed on the surface of tumor cells, function as antigens. These antigens act as distinctive flags, presenting a clear signal to the immune system that the cell is abnormal and potentially cancerous. This presentation of cancer-specific antigens on the cell surface is precisely what immune therapies, particularly those involving T-cells, are designed to detect and target.
The UCSF team ingeniously engineered immune T-cells to recognize these specific, alternatively spliced antigens. In laboratory experiments, these specially trained T-cells demonstrated a remarkable ability to identify and destroy glioma cells, showcasing the therapeutic potential of this discovery.
Expanding the Immunotherapy Arsenal: A Broader Spectrum of Targets
The implications of this discovery are far-reaching. The identification of antigens derived from alternative RNA splicing has the potential to dramatically expand the repertoire of targets available for immunotherapy. This is particularly significant for cancers that have historically proven resistant to conventional treatments, often due to a lack of readily identifiable mutations or antigens.
"We believe these initial antigens could be clinically actionable in the near future, paving the way for novel therapies for glioma patients," stated Hideho Okada, MD, PhD, a professor of neurosurgery at UCSF and co-corresponding author of the study. "However, this is just the beginning; we view these findings as the tip of the iceberg, and we are incredibly excited to explore the vast amount of data we’ve generated to uncover many more such antigens."
Navigating the "Sea of RNA" to Find Hidden Targets
The current paradigm of precision medicine often relies on two primary strategies: drugs that target specific genetic mutations driving cancer, or immunotherapies that harness the power of T-cells to recognize cancer-related antigens. However, many tumors, especially aggressive ones, lack the hallmark mutations targeted by current therapies. Furthermore, even when mutations are present, they may not be uniformly distributed throughout the tumor, allowing resistant subclones to survive and proliferate.
"One of the primary reasons we suspect many glioma therapies falter is their tendency to target only a specific subset of tumor cells. The remaining tumor population often escapes treatment unscathed," explained Joe Costello, PhD, a professor of neurosurgery at UCSF and the other co-corresponding author of the paper. "These newly identified antigens offer a powerful way to overcome this critical hurdle of brain tumor heterogeneity, where tumors are a mosaic of different cell types and genetic profiles."
The quest for these novel targets began with Darwin Kwok, PhD, a former graduate student in the Okada and Costello labs and now a UCSF medical student, who served as the study’s first author. His research focused on the intricate process of RNA splicing, which is known to generate multiple protein isoforms from a single gene.
"Many contemporary cancer therapies are predicated on the identification of unique DNA mutations found within tumors. However, we hypothesized that tumors might also exhibit altered RNA splicing patterns, leading to the generation of novel cancer-specific antigens," Kwok elaborated. "This approach offers an independent avenue for discovering therapeutic targets."
Kwok meticulously analyzed vast datasets from The Cancer Genome Atlas, a landmark program funded by the National Cancer Institute. He sifted through RNA sequencing data from thousands of tumor samples, specifically searching for uniquely spliced mRNA transcripts that were consistently present across multiple biopsies within the same tumor and across different patients. His search encompassed a broad range of cancer types, including those of the prostate, liver, colon, stomach, kidney, and lung.
To further validate his findings, Kwok collaborated with the UCSF Brain Tumor Center. He examined mRNA samples from gliomas donated by 51 UCSF patients. This meticulous approach involved collecting up to ten biopsies from each tumor, carefully documenting the precise anatomical location of each biopsy, and again searching for unusual mRNA signatures.
A Thousand Candidates, Thirty-Two Promising Targets
This comprehensive analysis yielded a remarkable discovery: nearly 1,000 unique cancer-specific mRNA transcripts that were common across different tumor types, patients, and even anatomical locations within a tumor. Crucially, none of these aberrant transcripts were detected in healthy tissue samples, confirming their tumor-exclusive nature.
However, not all mRNA molecules translate into proteins, and not all proteins are presented on the cell surface as antigens. Furthermore, not all antigens are recognized by the immune system. The researchers employed sophisticated computational modeling to predict which of these 1,000 mRNA candidates had the highest probability of progressing through this biological pathway to become a viable immunotherapy target.
This predictive modeling narrowed the field down to 32 promising antigen candidates, all arising from cancer’s aberrant RNA splicing. From this refined list, the team selected the top four for more intensive investigation. These four antigens were chosen based on their structural similarity to other known antigens that elicit a robust immune response, suggesting they were likely to be recognized by the immune system.
The subsequent experimental phase involved engineering cells to display these four candidate antigens. These engineered cells were then exposed to immune T-cells obtained from healthy blood donors. The results were highly encouraging: the researchers identified specific receptors on these naturally occurring immune cells that could reliably detect the cancer-specific antigens. This finding was a critical validation step, confirming that these novel antigens were indeed recognizable by the immune system and could potentially be leveraged for therapeutic purposes.
The probability of finding such complementary immune receptors in donated blood was statistically remote—described by Dr. Okada as "like one in five or 10 million." However, the team’s dedication paid off. For two of the top four antigens, they successfully identified matching immune receptors in two different donors, a testament to the power of their targeted approach.
Engineering a New Weapon: From Discovery to Therapy
With the identification of these key antigen-receptor pairs, the researchers proceeded to the next critical stage: creating a functional immunotherapy. They programmed laboratory-derived T-cells to express the identified immune receptors. These specially equipped T-cells were then unleashed upon glioma cells in controlled laboratory settings. The outcome was decisive: the engineered T-cells effectively recognized and eradicated the glioma cells, demonstrating a potent anti-cancer effect.
The success of these preclinical experiments has propelled the UCSF team to the next phase of research. They are currently testing this novel immunotherapy approach in animal models of cancer. If these studies prove successful, they aim to rapidly translate these findings into clinical trials for patients. The research team is also keenly aware that the 28 antigens that did not make the final cut in this initial study, along with countless other potential candidates identified from their data, warrant further investigation.
The precise biological reasons why so many different types of cancer converge on producing these same "jumbled" proteins remain an area of ongoing research. It is possible that these alterations are an unavoidable consequence of the fundamental chaotic nature of cancer cell biology. Regardless of the underlying cause, this discovery represents a significant new frontier in the fight against cancer.
"This breakthrough for cancer patients represents the pinnacle of collaborative effort at UCSF, encompassing expertise from computational modeling and laboratory validation to cutting-edge techniques in neurosurgery," Dr. Okada emphasized. "This is precisely the kind of innovative research that is needed to conquer the most challenging cancer cases and provide much-needed relief to our patients."
The implications of this research extend beyond glioma. The identification of a broader range of cancer-specific antigens, particularly those arising from RNA splicing, could benefit patients with a variety of solid tumors that have previously lacked suitable targets for immunotherapy. This could include a significant portion of difficult-to-treat cancers such as pancreatic cancer, triple-negative breast cancer, and various subtypes of lung and ovarian cancer.
The UCSF team’s methodical approach, combining deep genomic analysis with precise immunological validation, provides a robust framework for future drug discovery efforts. The ability to predict which aberrant proteins are most likely to be presented on the cell surface and recognized by the immune system significantly streamlines the development process, potentially shortening the timeline from discovery to clinical application.
This discovery also highlights the evolving understanding of tumor evolution. Cancers are not static entities; they are dynamic and constantly adapting. By targeting proteins that arise from fundamental cellular processes like RNA splicing, which are likely to be present throughout the tumor’s existence, immunotherapies may be less susceptible to the development of resistance mechanisms that often plague treatments targeting more transient genetic mutations.
Furthermore, the collaborative nature of this research, involving multiple departments and leveraging large-scale data resources like The Cancer Genome Atlas, underscores the increasing importance of interdisciplinary science in tackling complex medical challenges. The UCSF team’s work serves as a powerful model for how such collaborations can accelerate scientific progress and deliver tangible benefits to patients.
As the research progresses into animal models and potentially human trials, the scientific and medical communities will be watching with keen interest. The prospect of a new class of immunotherapies that can effectively target tumors previously considered untreatable offers a beacon of hope for millions of individuals worldwide facing the devastation of cancer. The UCSF researchers have not only uncovered new targets but have also provided a powerful new strategy for unlocking the immune system’s potential to fight cancer.
